Left Menu
Development News Edition

Precision Diabetes, LLC, Presents Data on Novel, Predictive Tests for Diabetes Complications at American Diabetes Association (ADA) Research Symposium: Advancing Precision Diabetes Medicine

PR Newswire | Lebanon | Updated: 08-10-2019 18:00 IST | Created: 08-10-2019 18:00 IST

Precision Diabetes, LLC, an emerging leader in precision diabetes diagnostics, announced results today from two landmark diabetes studies on its predictive tests for kidney and cardiovascular complications of diabetes. These results were reported at the inaugural ADA Research Symposium, "Advancing Precision Diabetes Medicine" in Madrid, Spain.

Data on Precision DKD™, a predictive blood test for diabetic kidney disease (DKD) measuring advanced glycation (AGEs) and oxidation end product (OPs) biomarkers, was presented as "Precision DKD: A Novel Test for Predicting Loss of Renal Function in Type 2 Diabetes." In this 169-patient study (Pima Indian Nephropathy Study), conducted over a median of 8 years, Precision DKD™ significantly outperformed traditional risk factors in predicting progression of kidney disease in patients with diabetes.

A study on Precision CVD™, a predictive blood test for cardiovascular disease (CVD) in patients with diabetes, was also presented. The study, "Early Prediction of Cardiovascular Disease with Oxidative and Advanced Glycation End Product Biomarkers in Type 1 Diabetes," was designed to assess the predictive value of oxidation and advanced glycation end product biomarkers for cardiovascular disease events in 459 patients over 30 years in the Diabetes Control and Complications Trial and the follow-up Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Results indicated that high levels of methionine sulfoxide (MetSO), an oxidative end product, and AGEs significantly improved prediction of cardiovascular events over traditional risk factors.

Dr. Paul Beisswenger, Professor of Medicine (Emeritus) at the Geisel School of Medicine at Dartmouth and Chief Scientific Officer at Precision Diabetes and primary investigator on both studies, said: "These predictive tests can alert patients with diabetes to their personal risk of developing the most serious diabetes complications, kidney and cardiovascular disease, years before these complications present clinically. Early identification of these complications will allow for the timely institution of preventive therapies."

Precision Diabetes, LLC, is also pleased to announce the appointment of Eric Button as Chief Executive Officer. He is a proven commercial stage leader in medical diagnostics with an impressive track record of bringing innovative tests to market, including the original PSA prostate cancer test and several novel diabetes tests. Eric holds an M.Sc. in Molecular Genetics from the University of British Columbia, and an MBA and BA in Biology from the University of North Carolina where he was a member of the Phi Beta Kappa honor society. "I am delighted to join Precision Diabetes. We are rapidly building out a comprehensive diabetes test product portfolio which will change the diabetes care paradigm and position the company to be the leaders in precision diabetes diagnostics," said Button.

About Precision Diabetes

Precision Diabetes, LLC, is an emerging leader in enabling precision medicine for diabetes through the use of novel diabetes biomarkers and algorithms. The company's mission is to revolutionize the diagnostic assessment of diabetes by providing a spectrum of unique diabetes tests, spanning the risk of developing diabetes to developing diabetic complications. The company's lead products, Precision DKD™ and Precision CVD™, determine the risk of developing kidney disease and cardiovascular disease, which remain the most serious diabetes complications.

Precision Diabetes, LLC, formerly PreventAGE Health Care, is located in Lebanon, New Hampshire, and is located in the Dartmouth Regional Technology Center.

Contacts

Heidi Eldred, Vice President of Marketing, Precision Diabetes
603-443-3624
heldred@preventagehealthcare.com


TRENDING

OPINION / BLOG / INTERVIEW

Post-COVID-19 Nigeria needs a robust Health Management Information System to handle high disease burden

Nigeria is among a few countries that conceptualised a health management information system HMIS in the early 90s but implementation has been a challenge till date. Besides COVID-19, the country has a huge burden of communicable and non-com...

Morocco COVID-19 response: A fragile health system and the deteriorating situation

Learning from its European neighbors, Morocco imposed drastic measures from the initial stages of the COVID-19 outbreak to try to contain its spread. The strategy worked for a few months but the cases have surged after mid-June. In this sit...

COVID-19: Argentina’s health system inefficiencies exaggerate flaws of health information system

You can recover from a drop in the GDP, but you cant recover from death, was the straightforward mindset of Argentinas President Alberto Fernndez and defined the countrys response to COVID-19. The South American nation imposed a strict...

Rwanda’s COVID-19 response commendable but health information system needs improvement

Rwanda is consistently working to improve its health information system from many years. However, it is primarily dependent on the collection and reporting of health data on a monthly basis. Besides, evaluation studies on Rwandas HIS publis...

Videos

Latest News

92 areas of England on COVID-19 watchlist; London Mayor wants stringent curbs

The UK governments COVID-19 watchlist has been expanded from 58 to 92, including all boroughs of London, as the rate of infection continues to rise across Britain. London Mayor Sadiq Khan said he has spoken to UK Prime Minister Boris Johnso...

Russia's COVID-19 cases rise to 1,143,571

Moscow Russia, September 26 ANISputnik Russia has registered 7,523 new cases of the coronavirus disease over the preceding 24 hours, up from 7,212 a day earlier, which brings the cumulative total to 1,143,571, the federal response center sa...

ISL: FC Goa sign Australian defender James Donachie for 2020-21 season

Ahead of the Indian Super League ISL 2020-21 season, FC Goa have announced the signing of Australian defender James Donachie on a one-year loan deal from A-League side Newcastle Jets. The centre-back becomes the Gaurs ninth new signing ahea...

Realme teases new 7-series phone in India; expected to be Realme 7i

Realme 7i is expected to be launched in India next month along with several products including a smartwatch, 4K TV, wireless buds, soundbar, etc.Realme India CEO Madhav Seth on Saturday teased a new 7-series smartphone with a 64-megapixel q...

Give Feedback